Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

radium-223

- PMLiVE

Eylea growth closes the gap with Lucentis

Bayer/Regeneron’s drug eye disease drug set for blockbuster status

- PMLiVE

Kythera bags FDA approval for double chin therapy

Comes as cosmetics industry sees major growth

- PMLiVE

Payment to docs rules ‘an opportunity for pharma’

The industry’s reputation can be boosted by openness, say pharma compliance leaders

ABPI London offices

Pharma must engage on the affordability question, says ABPI

UK pharma trade body says the industry must be willing to discuss drug pricing

- PMLiVE

Quality in Care anticoagulation programme open for entry

PMGroup's QiC programme aims to recognise best practice in care in the UK

- PMLiVE

Pfizer breast cancer drug shines in latest trial

Study with Ibrance stopped early because of its success

- PMLiVE

AstraZeneca gains FDA orphan status for new cancer drug

Gains a longer patent life for the investigational lung disease drug

Gilead Sciences

Sovaldi pushes Gilead to the top of US pharma list

Blockbuster hep c pill sees the firm go from fourteenth to first in just one year

- PMLiVE

AstraZeneca and EHR firm to use drug alert system

Firm will team up with Practice Fusion to help keep patients on the right treatment pathway

- PMLiVE

AstraZeneca and PatientsLikeMe team up on real-world data

Two groups hoping to harness the power of the patient forum network

National Institute for Health and Care Excellence NICE logo

UK market access issues put on hold during election

NICE appraisals and Cancer Drugs Fund appeals will not be undertaken until May

Can Cinderella save us?

UK government warns over antibiotic resistant deaths

Cabinet Office document says the next 20 years is a crucial period for creating new medicines

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links